Expand STRO Menu
STRO MENU

STRO Stock Posts


Unusual Option Volume

STRO Sutro Biopharma5.25+0.92 (+21.3%)

Sutro Biopharma trades 3,541 contracts. News: Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
View Details...
STRO #SutroBiopharma stock declines -20.9% in premarket,

Premarket Decliner

STRO Sutro Biopharma14.57-0.53-3.5%

Premarket:11.52-3.05 (-20.9%)

Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

PRNewswireThu, 6-Jan 7:00 AM
STRO #SutroBiopharma stock declines -12.1% in after hours trading. See the latest news.

After Hours Decliner

STRO Sutro Biopharma14.57-0.53-3.5%

After Hours:12.80-1.77 (-12.2%)

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

PRNewswireWed, 5-Jan 4:30 PM
STRO #SutroBiopharma stock declines -12.1% in after hours trading. See the latest news.

After Hours Decliner

STRO Sutro Biopharma14.57-0.53-3.5%

After Hours:12.80-1.77 (-12.2%)

Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer

PRNewswireWed, 5-Jan 4:30 PM
STRO #SutroBiopharma stock increases 20.0% after hours.

After Hours Gainer

STRO Sutro Biopharma17.00+0.65+4.0%

After Hours:20.40+3.40 (+20.0%)

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

PRNewswireThu, 3-Dec 4:30 PM
STRO #SutroBiopharma stock increases 17.6% after hours.

After Hours Gainer

STRO Sutro Biopharma17.00+0.65+4.0%

After Hours:20.00+3.00 (+17.7%)

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

PRNewswireThu, 3-Dec 4:30 PM
Load Earlier Posts